Exagen Inc stock (US30063K1051): 13G filing shows 9.9% stake

A new SEC filing shows Jorey Chernett beneficially owned 2.41 million Exagen shares, or 9.9% of the company, as of May 19, 2026.

Exagen shares drew attention after a new SEC filing showed investor Jorey Chernett beneficially owned 2,413,901 common shares, equal to 9.9% of the company’s outstanding stock, as of May 19, 2026. The filing was posted through StockTitan and cites Exagen’s share count from its May 11 Form 10-Q, giving US investors a fresh ownership data point to watch.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exagen Inc
• Sector/industry: Healthcare diagnostics
• Headquarters/country: United States
• Home exchange/listing venue: Nasdaq: XGN
• Trading currency: USD
• Key revenue drivers: Autoimmune testing and related diagnostic services

Exagen Inc: ownership filing puts a spotlight on the stock

The filing says Chernett held the shares as of the close of business on May 19, 2026, and that the percentage calculation was based on 24,159,839 shares outstanding as of May 6, 2026, as disclosed in Exagen’s quarterly report. A Schedule 13G/A is generally associated with passive holdings, so the document is more about position size than an operating change at the company.

For retail investors in the US, the update matters because ownership shifts can affect how a small-cap healthcare stock is traded and discussed. Exagen operates in diagnostics, a segment that often depends on reimbursement trends, physician adoption, and test utilization, so new stake disclosures can add another layer of interest beyond day-to-day share price moves.

Main business and revenue drivers for Exagen Inc

Exagen’s business centers on laboratory testing for autoimmune diseases, including laboratory-developed diagnostic services that help physicians assess patients with complex symptoms. The company’s revenue mix is tied to how often clinicians order its tests, how successfully it converts testing into reimbursable sales, and how payer policies evolve over time.

That makes the company different from a software or consumer stock: sales can depend on clinical workflows, coverage decisions, and the pace of adoption in specialty medicine. Investors watching Exagen often focus on volume trends, gross margin, and the degree to which results reflect higher testing demand rather than one-time events.

Because the business serves the US healthcare system, Exagen also has direct exposure to American reimbursement and provider networks. For US investors, that can make the stock more sensitive to policy and commercial execution than to broad consumer demand alone.

Why Exagen matters for US investors

Exagen is listed on Nasdaq and trades in US dollars, which makes it accessible to domestic retail traders looking at small-cap healthcare names. Stocks in this category can move sharply when ownership, earnings, or clinical and reimbursement updates arrive, even if the fundamental story changes more slowly.

The latest filing does not by itself change Exagen’s business outlook, but it confirms that a meaningful block of shares sits with one reported holder. In smaller healthcare companies, that can influence liquidity, sentiment, and the way investors frame the stock before the next operational update.

Conclusion

Exagen’s latest ownership filing does not change the company’s product line or operating model, but it does add a fresh disclosure point for investors monitoring the stock. The 9.9% stake reported by Jorey Chernett is notable because it shows meaningful ownership in a relatively small listed healthcare company. For US investors, the key question now is whether future company updates on testing demand, reimbursement, and operating performance will provide a stronger catalyst than this filing alone.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.